Australia's most trusted source of pharma news
Monday, 25 March 2019
Lost Your Access?
New version of same old tactic
Latest media blast is old 'bad pharma' tune in new guise.
Media attacks Pfizer over Lyrica
Fairfax outlets allege manipulation of patient groups.
What Fairfax ignored on Lyrica
Background material shows much left out of damaging article.
Hunt pushes pre-PBS subsidies
Some meds may be funded during reimbursement process.
GPs on political warpath
Urged to lobby patients and pollies as election nears.
Patients protest slow PBS
Breast Network says meds access still takes too long.
Pfizer celebrates 100 days
Reveals more on motivation, effect of Sydney CBD move.
Japanese pharma sets up in Oz
Search on for a GM; two drugs already in pipe.
How PBAC stalled a dream run
Record-breaking drug too expensive at first submission.
Seqirus scores PBS double
Wins two of three remaining pre-election PBS berths.
Novartis climbs back to top
Year begins with a return to head of PBS top ten.
US pharmas set up in Aust
Two companies move to Melbourne, bringing 100-plus new jobs.
Hunt's $1m+ expense claim
Domestic trips in second half of '18 the big ticket item.
Court stays Sandoz $26m bill
Temporary injunction as generic company appeals.
Xeljanz safety issue hits Aust
Pfizer is informing doctors of high dose risk.
Grattan to give health script
Duckett joins panel on national priorities.
R&D reform delay costs $850m
Budget predictions down the drain.
GSK makes asthma move
Plus new breast cancer option.
EU expands Mabthera
Label includes pemphigus vulgaris treatment.
Top of the Hill
Could everything old be new?
Hunt on way out of Health, what now for pharma?
Events & Conferences
© 2003 - 2019 Lush Media
Pharma in Focus
Jolly Good Design